IGI announced a robust pipeline comprising three oncology molecules presently undergoing clinical trials, focusing on multiple myeloma, acute myeloid leukemia, and solid tumors.

[14] Glenmark Pharmaceuticals announced that it entered into an exclusive licensing agreement with Australia's Sequirus to commercialize its nasal spray Ryaltris[15] which is a fixed-dose combination nasal spray of an antihistamine and a steroid, as a treatment for seasonal allergic rhinitis (SAR).

[22] This product launch additionally signifies Glenmark's entry into the domain of injectable anti-diabetic therapies.

[23] On 25 January 2024 Glenmark Pharmaceuticals, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License agreement to develop, register, commercialize, Envafolimab for the oncology indication for India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America.

Glenmark Pharmaceuticals announced on January 31 that they have collaborated with Pfizer to launch Abrocitinib - which is an oral treatment for moderate-to-severe cases of atopic dermatitis or AD.

[24] The drug which is originally developed by Pfizer will be sold under the brand name JABRYUS by Glenmark Pharmaceuticals.